SCHOTT Pharma Forecasts FY 25 Slowdown Due to Reduced Syringe Growth

• SCHOTT Pharma AG & Co. KGaA forecasts slower growth for FY 25 due to lower demand for syringes from a large customer.
• The company expects revenue growth in a high single-digit to a low double-digit percentage range for fiscal year 2024/2025, starting from 1st October 2024.
• This forecast deviates from the current market consensus.
• The EBITDA margin expansion will be weaker than currently expected in the market due to the lower than expected revenue growth.
• Despite this temporary effect, SCHOTT Pharma confirms its mid-term forecast and its forecast for the current fiscal year.
• The forecasts are based on constant currencies.

The price of SCHOTT Pharma at the time of the news was 35,60EUR and was down -2,92 % compared with the previous day.
14 minutes after the article was published, the price was 31,32EUR this corresponds to a minus of -12,02 % since publication.
At this time, the index SDAX was at 15.067,58PKT (+1,31 %).

SCHOTT Pharma

-1,44 %

-0,85 %

-23,96 %

-21,30 %

+9,89 %

ISIN:DE000A3ENQ51WKN:A3ENQ5

• Intraday
• 5 Tage
• 1 Monat
• 3M
• Max